Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
NFL
U.S.
2024 Election
Local
World
Science
Technology
AI
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Zepbound Tops Wegovy for Weight Loss
Zepbound leads to more weight loss than Wegovy, drugmaker Eli Lilly says
Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from drugmaker Eli Lilly.
Eli Lilly's Zepbound beats Wegovy in head-to-head weight loss trial
Eli Lilly said patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy in a study.
Eli Lilly Chief Scientific Officer explains Zepbound's weight loss advantage
Dan Skovronsky, Eli Lilly Chief Scientific Officer, joins 'Fast Money' to talk Zepbound's recent trial results and what it means for Eli Lilly's future growth.
Lilly invests $3 billion to expand Wisconsin plant
Eli Lilly CEO says Mounjaro maker may consider other Wisconsin sites for new plants
Fast-growing drugmaker Eli Lilly and Co. would consider Wisconsin sites for new plants beyond a $3 billion project the company announced in Kenosha County, the company’s CEO told the Milwaukee Business Journal.
Eli Lilly invests $3B to expand Wisconsin factory to help meet demand for Mounjaro, Zepbound
Eli Lilly is spending another $3 billion to bulk up manufacturing as the drugmaker seeks to stoke production of some blockbuster drugs and future products. Lilly said Thursday it will expand a Kenosha County,
Eli Lilly to Invest $3B in Wisconsin Plant to Meet Obesity Drug Demand
Eli Lilly LLY recently announced its plans to spend $3 billion to expand the manufacturing facility in Wisconsin that was acquired earlier this year from Nexus Pharmaceuticals. Management expects to start construction on this expansion next year.
Yahoo Finance
1d
The Weight Loss Drug Race Heats Up: Eli Lilly's Zepbound Outperforms Wegovy in Weight Loss Trials
Eli
Lilly
(NYSE:LLY) has been making headlines recently with its weight-loss drug
Zepbound
(tirzepatide).
Eli
Lilly
...
Seeking Alpha on MSN
1d
Lilly's Zepbound will first be given in the UK to those with 'highest clinical need'
Given the strong demand expected for
Eli
Lilly
's (NYSE:LLY) weight loss treatment
Zepbound
(tirzepatide) in the UK, the ...
4d
Eli Lilly’s Growth Driven by Strong Prescription Trends for Mounjaro and Zepbound
Analyst Terence Flynn from Morgan Stanley maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) and increased the price target ...
3h
Eli Lilly Investments In Production Reach $23 Billion With Additional $3 Billion Expansion At US Facility
Eli Lilly And Co (NYSE:LLY) announced a $3 billion expansion of its Kenosha County, Wisconsin, manufacturing facility to ...
1d
on MSN
Lilly to Boost Obesity Drug Supply With $3 Billion Expansion
Eli Lilly & Co. is spending another $3 billion to build out its US manufacturing footprint as it ramps up production of its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Mounjaro
Wegovy
Novo Nordisk
Amgen
Feedback